TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02331524

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health Coaching/Home Exercise
Description: The Health Coaching/Home Exercise group will receive 12 weekly health coaching and physical therapy visits for 3 months. Health coaching will be provided by a trained, highly experienced health and wellness coach. In-home health coaching sessions will be provided monthly (total of 3) with the remaining 9 sessions provided telephonically. Initial health coaching sessions will include the utilization of motivational interviewing to establish individualized, three-month goals related to symptoms, function, and/or daily activity, with subsequent sessions celebrating successes in and/or identifying barriers to achieving these goals.
Study: NCT01057914

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutritional supplementation with a liquid formula
Description: The patient consumes 400 kcal from a liquid supplementation formula

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary advice
Description: The patient receives dietary advice for one hour during the hospital stay.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combination of supplement and dietary advice
Description: The patient receives dietary advice for one hour during the hospital stay and consumes 400 kcal from liquid supplementation formula for six month after discharge.
Study: NCT00741169

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin
Description: 600 mg taken by mouth once daily for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC435350+rifampin
Description: The combination of TMC435350 200 mg + rifampin 600 mg both taken by mouth once daily for 7 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC435350+rifampin
Description: The combination of TMC435350 200 mg + rifampin 600 mg both taken by mouth once daily for 7 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC435350+rifampin
Description: The combination of TMC435350 200 mg + rifampin 600 mg both taken by mouth once daily for 7 days.
Study: NCT01742078

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2541546 - IV
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2541546 - IV
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2541546 - IV
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2541546 - IV
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2541546 - IV
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2541546 - IV
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2541546 - IV
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2541546 - SC
Description: Administered SC
Study: NCT03336515

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Group B-Postural device no activated
Description: General recommendation not sleeping in supine position and the postural device without any activation (placebo)
Study: NCT00741169

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC435350+rifampin
Description: The combination of TMC435350 200 mg + rifampin 600 mg both taken by mouth once daily for 7 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC435350+rifampin
Description: The combination of TMC435350 200 mg + rifampin 600 mg both taken by mouth once daily for 7 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC435350+rifampin
Description: The combination of TMC435350 200 mg + rifampin 600 mg both taken by mouth once daily for 7 days.
Study: NCT02234765

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Primary Care-based management
Description: Patients will be diagnosed and follow-up in Primary Care.
Study: NCT03336515

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Group A-General Recommendation
Description: General recommendation not sleeping in supine position
Study: NCT01742078

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered IV or SC
Study: NCT03400137

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Increasing of intraocular pressure (IC)
Description: intraocular pressure will be increased using an ophthalmodynanometer

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Increasing of intraocular pressure (IC)
Description: intraocular pressure will be increased using an ophthalmodynanometer

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Increasing of intraocular pressure (IC)
Description: intraocular pressure will be increased using an ophthalmodynanometer
Study: NCT02608034

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Itraconazole will be administered as a 200 mg oral solution QD during Part 1 only for 20 consecutive days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin
Description: Rifampin will be administered as a 600 mg oral solution QD during Part 2 only for 20 consecutive days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemurafenib
Description: Vemurafenib will be administered in both Part 1 and Part 2 at a dose of 960 mg BID for at least 40 conseutive days.
Study: NCT02246023

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Flexible bronchoscopy in moderate sedation
Description: Flexible bronchoscopy for diagnosis of lung cancer, sarcoidosis or interstitial pneumonia in moderate sedation with propofol;

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Flexible bronchoscopy in moderate sedation
Description: Flexible bronchoscopy for diagnosis of lung cancer, sarcoidosis or interstitial pneumonia in moderate sedation with propofol;
Study: NCT02234765

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard management
Description: Standard management according to Spanish Respiratory Society guidelines in Sleep Unit.
Study: NCT02246023

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Oxygen saturation
Description: Continuous measurement of oxygen saturation;

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Oxygen saturation
Description: Continuous measurement of oxygen saturation;

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Blood pressure
Description: Measurement of non-invasive blood pressure every 3 minutes

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blood pressure
Description: Measurement of non-invasive blood pressure every 3 minutes

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Propofol dosage
Description: Report of dose adjustments und cumulative propofol dosage;

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Propofol dosage
Description: Report of dose adjustments und cumulative propofol dosage;

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Recovery time after bronchoscopy
Description: Recovery time after bronchoscopy from removal of bronchoscope to eye opening/answer to verbal stimuli (whatever comes first)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Recovery time after bronchoscopy
Description: Recovery time after bronchoscopy from removal of bronchoscope to eye opening/answer to verbal stimuli (whatever comes first)
Study: NCT01650792

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Study: NCT03451500

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carbidopa-levodopa
Description: See previous

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: carbidopa-levodopa
Description: See previous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carbidopa-levodopa
Description: See previous
Study: NCT02116816

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Polyphenol
Description: Polyphenol
Study: NCT00185887

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Terbutaline
Description: Terbutaline 250 micrograms intravenously for intrapartum fetal resuscitation. Nitroglycerine 400 micrograms intravenously for intrapartum fetal resuscitation.
Study: NCT03198780

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breathing Awareness
Description: Participants will use a pulse-oximeter and biofeedback app to guide them through pursed-lip breathing training.
Study: NCT02026206

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: low-level light therapy
Description: we used a skin-adhesive LLLT device called the Color DNA-WSF (Color Seven Co., Seoul, Korea) which consists of body for power supply and two microprocessor-controlled light-emitting diodes. We selected two acupuncture points, conception vessel 4 (CV4; Guanyuan) and CV6 (Qihai), for treating dysmenorrhea. The participants attached the skin-adhesive LLLT device probes to both acupuncture points according to treatment schedule.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: we used a placebo skin-adhesive LLLT device called the Color DNA-WSF (Color Seven Co., Seoul, Korea) which consists of body for power supply and two microprocessor-controlled light-emitting diodes. We selected two acupuncture points, conception vessel 4 (CV4; Guanyuan) and CV6 (Qihai), for treating dysmenorrhea. The participants attached the placebo skin-adhesive LLLT device probes to both acupuncture points according to treatment schedule.
Study: NCT00440817

Intervention type: OTHER
Intervention: No intervention
Description: All treatments are prescribed by a physician on the basis of usual clinical practice.
Study: NCT04873076

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Audiovisual distraction using 2d video glasses from HappyMed GmbH
Description: Patients receive optical and acustical relaxing material during the procedure by using 2d video glasses from HappyMed GmbH
Study: NCT02524587

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: radio stereometric analysis (RSA) of the acetabular

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: acetabular polyethylene vitamys®
Study: NCT03276780

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Counseling
Description: Both groups receive smoking cessation counseling although one is focused on medication adherence and addressing barriers to adherence while the other is focused on standard behavioral strategies to quit smoking

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Counseling
Description: Both groups receive smoking cessation counseling although one is focused on medication adherence and addressing barriers to adherence while the other is focused on standard behavioral strategies to quit smoking

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: combination NRT
Description: Both groups will receive combination NRT to help with smoking cessation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: combination NRT
Description: Both groups will receive combination NRT to help with smoking cessation
Study: NCT03667079

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: integrated delivery of deworming and vaccination
Description: integrated delivery of mass drug administrations, one targeting humans (deworming) and one targeting animals (rabies vaccination)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mass deworming only
Description: Delivery of mass deworming to people only

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mass vaccination of dogs
Description: Delivery of mass vaccination of dogs only
Study: NCT01689662

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tc 99m EC20
Study: NCT01429051

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal Fentanyl Spray (INFS)
Description: Applied as 1 puff (= 1 dose) in one nostril, or applied as two puffs (= 2 doses, 1 in each nostril) with ten minutes apart.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching intranasal placebo spray
Study: NCT03589235

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: A free gingival graft
Description: A free gingival graft will be used for the treatment of gingival recession

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: A free gingival graft
Description: A free gingival graft will be used for the treatment of gingival recession

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: A Platelet-Rich Fibrin dressing
Description: A Platelet-Rich Fibrin dressing (PRF) will be applied in both donor and receiving sites after the free gingival graft.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: A non-eugenol-based dressing
Description: A non-eugenol-based dressing (Coe-Pak™) will be applied in both donor and receiving sites after the free gingival graft.
Study: NCT00862017

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: MSg supplementation

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: NaCl supplementation
Study: NCT01939041

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: InMotion3 (IMT)
Description: Participant will practice about 2-5-minute of passive, 25-30-minute of assisted-active, and 3-5-minute of active motions in wrist and forearm respectively. The wrist motions will include flexion, extension, radial deviation, and ulnar deviation. Forearm motions will include supination and pronation. During the practice, a visual display will provide online visual feedback of accuracy and coordination success.
Study: NCT02579434

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam I.V.
Description: Midazolam I.V. 1mg/ml

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam I.V.
Description: Midazolam I.V. 1mg/ml

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam I.V.
Description: Midazolam I.V. 1mg/ml

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam I.V.
Description: Midazolam I.V. 1mg/ml
Study: NCT01939041

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bi-Manu-Track (BMT)
Description: The Bi-Manu-Track enables the symmetrical practice of 2 movement patterns in conjunction with computer games: forearm pronation-supination and wrist flexion-extension. Each movement has three computer-controlled modes: (1) passive-passive, with both arms being moved by the machine with speed and range of motion individually adjustable; (2) active-passive, with the nonaffected arm driving the affected arm in a mirror-like fashion; and (3) active-active, with both arms actively moving against resistance. The speed of movement, the amount of resistance, and the range of movement can be adjusted individually. The device has a mechanical breaking of the movement when the torques exceeded 4 Nm, emergency breaks in the reach of the patients, skin friendly materials, and minimal risk for contusions.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control intervention (CI)
Description: he control group's therapy will be designed to control for the duration and intensity of the robot-assisted training (90 min/day, 5 days/wk, for 4 wk). The therapeutic activities in the control group will involve passive range of motion, weight bearing, stretching, strengthening of the paretic arm, gross motor activities, coordination tasks, unilateral and bilateral fine motor tasks, transition, mobility, and posture/balance.
Study: NCT01804452

Intervention type: OTHER
Intervention: Observational Study
Study: NCT04227028

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brigatinib
Description: Given PO
Study: NCT02996812

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exendin (9-39)
Study: NCT01487200

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FX006 40 mg
Description: single 3 mL IA injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FX006 60 mg
Description: single 3 mL IA injection
Study: NCT02996812

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exendin (9-39)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exendin (9-39)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exendin (9-39)
Study: NCT04188951

Intervention type: DRUG
Group type: OTHER
Intervention: Pembrolizumab 25 MG/1 ML Intravenous Solution [KEYTRUDA]
Description: Patients will receive 17 cycles of pembrolizumab via IV infusion of 200 mg over a period of 30 minutes, every 3 weeks starting no later than 90 days from the date of salvage head and neck therapy.
Study: NCT01487200

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TCA IR 40
Description: single 1 mL IA injection
Study: NCT04412954

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smartphone + Text Messaging with Health Coach
Description: The program includes (1) use of a free commercially available smartphone application program for 12 months, (2) a wearable Fitbit Charge device that will be provided by the study to monitor active minutes, and (3) one 45-minute behavioral counseling session focused on healthy eating and exercise and (4) personalized text messaging for 6 months by a health coach. The health coach will not send feedback during months 6-12. The intervention will be fully self-directed in these months, as there will be no contact between the 6 months visit and 12-month visit.
Study: NCT02085213

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glyceryl Trinitrate
Study: NCT02709850

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IONIS ANGPTL3-LRx

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IONIS ANGPTL3-LRx

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IONIS ANGPTL3-LRx
Study: NCT03126916

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Hematopoietic Stem Cell Transplantation
Description: Undergo autologous HSCT
Study: NCT02709850

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IONIS ANGPTL3-LRx

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IONIS ANGPTL3-LRx
Study: NCT03126916

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Hematopoietic Stem Cell Transplantation
Description: Undergo autologous HSCT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Hematopoietic Stem Cell Transplantation
Description: Undergo autologous HSCT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Hematopoietic Stem Cell Transplantation
Description: Undergo autologous HSCT
Study: NCT02581007

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: fludarabine (30mg/m2) given every day starting on Day -6 through Day -2;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: cyclophosphamide (50mg/kg) given every day starting on Day 3 through Day 4.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplant
Study: NCT01298713

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamoxifen
Description: 20mg daily (1 cap) until unbearable toxicity or progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Description: 20mg daily (1 cap) until unbearable toxicity or progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: 10mg daily (2 caps of 5mg) until unbearable toxicity or progression
Study: NCT01457261

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salbutamol
Description: Radiolabelled salbutamol to be administered as a monodisperse particle via a spinning top aerosol generator or else as a polydisperse mist via a nebuliser or metered dose inhaler.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salbutamol
Description: Radiolabelled salbutamol to be administered as a monodisperse particle via a spinning top aerosol generator or else as a polydisperse mist via a nebuliser or metered dose inhaler.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salbutamol
Description: Radiolabelled salbutamol to be administered as a monodisperse particle via a spinning top aerosol generator or else as a polydisperse mist via a nebuliser or metered dose inhaler.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salbutamol
Description: Radiolabelled salbutamol to be administered as a monodisperse particle via a spinning top aerosol generator or else as a polydisperse mist via a nebuliser or metered dose inhaler.
Study: NCT03854786

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Oxyjun
Description: Oxyjun is the proprietary single ingredient product containing high concentrated well standardized aqueous extract of Terminalia arjuna.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Pacebo
Description: Methyl Crystalline Cellulose
Study: NCT04472247

Intervention type: DIAGNOSTIC_TEST
Intervention: Continuous EEG and EMG monitoring, with derived variables
Description: All patients are monitored during their ICU stay by frontal EEG and EMG measuring devides, which are already in clinical use.
Study: NCT03591939

Intervention type: DIAGNOSTIC_TEST
Intervention: laboratory test
Description: role of T- regulatory cells in the patients of diabetic nephropathy

Intervention type: DIAGNOSTIC_TEST
Intervention: laboratory test
Description: role of T- regulatory cells in the patients of diabetic nephropathy
Study: NCT01534923

Intervention type: BEHAVIORAL
Intervention: surveys
Description: The intervention will be the audio-recording of the physician-patient consultation, patient and doctor surveys. These audio recordings will be coded. It will also include follow-up phone calls with patients.
Study: NCT03126916

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Hematopoietic Stem Cell Transplantation
Description: Undergo autologous HSCT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study: NCT00395174

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza Vaccination
Description: 0.5mL dose for intramuscular injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Influenza Vaccination
Description: 0.5mL dose for intramuscular injection